Open Orphan and Codagenix have received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct a Phase I study of its COVID-19 vaccine.
Open Orphan has announced the signing of a £2.5m contract by its subsidiary hVIVO to conduct an influenza human challenge study with a US biotechnology company.